Presentation is loading. Please wait.

Presentation is loading. Please wait.

Proprietary & Confidential 1 Drug Efficacy in the Wild Tim Vaughan 8-Sep-2011.

Similar presentations


Presentation on theme: "Proprietary & Confidential 1 Drug Efficacy in the Wild Tim Vaughan 8-Sep-2011."— Presentation transcript:

1 Proprietary & Confidential 1 Drug Efficacy in the Wild Tim Vaughan 8-Sep-2011

2 Proprietary & Confidential 2 PatientsLikeMe – Three brothers’ story

3 Proprietary & Confidential 3 ALS − Rare neurologic disease

4 Proprietary & Confidential 4 ALS − Time is of the essence

5 Proprietary & Confidential 5 Contents  PatientsLikeMe  Why is MikeFromFinland taking lithium?  Lithium delays progression of ALS?!  PatientsLikeMe’s observational study  Finding patients like me  Results  Predictive modeling / What is my outcome?  Concluding remarks

6 Proprietary & Confidential 6 PatientsLikeMe web site

7 Proprietary & Confidential 7 Stephen Heywood (alsking101)

8 Proprietary & Confidential 8 Data collection

9 Proprietary & Confidential 9 Why is Mike taking lithium? Lithium

10 Proprietary & Confidential 10 Lithium delays progression of ALS?! Fornai et al., PNAS 105:2052-2057 (2008)

11 Proprietary & Confidential 11 The observational study germinates

12 Proprietary & Confidential 12 Timeline

13 Proprietary & Confidential 13 Patients track their progress

14 Proprietary & Confidential 14 The “kitchen sink” plot

15 Proprietary & Confidential 15 Random control may not be a “patient like me”

16 Proprietary & Confidential 16 Demographics – age

17 Proprietary & Confidential 17 Demographics – onset site

18 Proprietary & Confidential 18 Demographics – sex

19 Proprietary & Confidential 19 Matching algorithm

20 Proprietary & Confidential 20 Matching across the entire sample

21 Proprietary & Confidential 21 Pre-treatment progression bias reduced

22 Proprietary & Confidential 22 Results of lithium treatment

23 Proprietary & Confidential 23 Kaplan-Meier for patients & data

24 Proprietary & Confidential 24 Biases and other stuff that worried us  Self-selection for treatment  “Recruitment bias”  Data reported (vs. data opportunity)  Outliers (e.g. PMA and PLS)  “Optimism bias” at treatment start

25 Proprietary & Confidential 25 What Mike (and PatientsLikeMe) can learn

26 Proprietary & Confidential 26 Conclusions  Savvy patients are using the internet in creative ways to understand and improve their health  Structured, self-reported patient data has profound value, despite being subject to bias (like all patient data!)


Download ppt "Proprietary & Confidential 1 Drug Efficacy in the Wild Tim Vaughan 8-Sep-2011."

Similar presentations


Ads by Google